Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Rheumatrex
gptkb:Trexall |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
alcoholism
liver disease pregnancy immunodeficiency |
| gptkbp:dosage_form |
injection
|
| gptkbp:effective_date |
2013-01-09
|
| gptkbp:formulation |
auto-injector
|
| https://www.w3.org/2000/01/rdf-schema#label |
Otrexup
|
| gptkbp:ingredients |
gptkb:methotrexate
|
| gptkbp:is_used_for |
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis gptkb:psoriatic_arthritis |
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:manufacturer |
Antares Pharma
|
| gptkbp:marketed_as |
gptkb:Otrexup
|
| gptkbp:packaging |
single-dose prefilled syringe
|
| gptkbp:side_effect |
fatigue
headache nausea alopecia stomatitis |
| gptkbp:social_structure |
C20 H22 N8 O5
|
| gptkbp:storage |
room temperature
|